OUR VISION
A world where no one dies of lung cancer

OUR MISSION
LUNGevity Foundation is firmly committed to having an immediate impact on improving quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease.

We bring together world-class scientific minds, passionate advocates, and an efficient and effective organization.

THINGS YOU SHOULD KNOW...
• It is ok to ask for a second opinion
• Be sure to get your tumor tested for known biomarkers
• There may be a clinical trial available for you
• Ask about palliative care and pulmonary rehabilitation

Did you know LUNGevity has an array of resources for you or your caregiver to help you navigate your lung cancer journey?

Visit www.LUNGevity.org to learn more.
Targeted therapy is a type of treatment that attacks specific cells in the body to stop them from growing. It is a precision treatment that is based on the characteristics of an individual’s own cells.

The specific cells attacked by targeted therapy are those with changes in their DNA, or mutations, in how the cell normally functions. These mutations, called driver mutations, cause the cells to grow and divide uncontrollably, leading to the formation of tumors.

Targeted therapy is unlike standard chemotherapy, which attacks all cells that grow and divide quickly, not just cells with cancer-causing driver mutations.

In lung cancer, more than 20 different driver mutations have so far been discovered in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Right now, scientists have the most information about driver mutations in a subtype of NSCLC called adenocarcinoma, and they are making progress in learning about the others.

An individual’s eligibility for targeted therapy for their adenocarcinoma depends on the presence of one of the driver mutations for which there is either a U.S. Food and Drug Administration (FDA)-approved targeted therapy (currently ALK, EGFR, ROS1, and BRAF V600E) or an appropriate clinical trial. Clinical trials are research studies that test new treatment approaches.

Driver mutations in lung adenocarcinoma

- **EGFR-sensitizing** 15%
- **EGFR other** 2%
- **KRAS** 25%
- **ALK** 7%
- **HER2** 2%
- **BRAF V600E** 2%
- **BRAF other** 1%
- **ROS1** 2%
- **RET** 2%
- **NTRK1** 0–5%
- **MET** 3%
- **MAP2K1** 0–5%
- **PIK3CA** 1%
- **NRAS** 0–5%
- **>1 mutation** 3%
- **Unknown** 31%

**CHECK WITH YOUR DOCTOR**

**Biomarker testing** is a way for your doctors to gather as much information as possible about your unique lung cancer. Ask about being tested. The results of these tests will indicate whether you have a driver mutation and will help determine whether any of the FDA-approved targeted therapies are right for you as part of your treatment plan.

**Clinical trials** offer an important treatment option for people affected by lung cancer. Advances in targeted therapies are based on information learned from patients who were enrolled in clinical trials. If you are considering participating in a clinical trial, start by asking your doctor whether there is one in your area for which you might qualify. Promising drugs to target other driver mutations in both adenocarcinoma and other types of lung cancer are currently being studied.

To learn more about:
- the driver mutations that cause lung cancer,
- getting your tumor tested for driver mutations,
- which targeted therapy options are currently available for those with a driver mutation, and
- whether targeted therapy might be a good treatment option for you,

visit [https://LUNGevity.org/for-patients-caregivers/](https://LUNGevity.org/for-patients-caregivers/) get-educational-materials to download a copy of the LUNGevity Targeted Therapy booklet.

“The Targeted Therapy patient education booklet is a great resource for my patients. I use it to explain how targeted therapies fit into their treatment options.”

**ZOFIA PIOTROWSKA, MD**
Massachusetts General Hospital Cancer Center and Harvard Medical School

I am interested in information about:
- Biomarkers
- Clinical trials
- Immunotherapy
- Lung adenocarcinoma
- Squamous cell lung cancer
- Targeted therapy
- Support services/Mentors

I am a (choose one):
- **Patient/Survivor**
- **Caregiver**
- **Friend or family member**
- **Healthcare provider**
- **Organization**
- **Industry partner**
- **Other**

Visit us on the web at: [www.LUNGevity.org](http://www.LUNGevity.org)
or contact us directly at: info@LUNGevity.org
312.407.6100